相关实验视频

Updated: May 5, 2026

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits

Published on: March 16, 2016

实验证据表明,阿尔茨海默病大脑中容易扩散的Aβ形式具有播种活动

Simin Song^1,2, Qianmin Liu^1,3, Ruixiang Chen^1,4

¹Shenzhen Key Laboratory of Neuroimmunomodulation for Neurological Diseases, Shenzhen- Hong Kong Institute of Brain Science, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China.

Acta neuropathologica communications

|May 23, 2025

概括

来自阿尔茨海默病 (AD) 大脑的粉样蛋白-β (Aβ) 的扩散形式加速了小鼠模型中的粉样蛋白病理和认知衰退. 这些可溶性Aβ物种启动和传播AD类变化,突出显示了它们的毒性潜力.

科学领域:

神经科学是一个神经科学.
生物化学生物化学
病理学病理学病理学

背景情况:

粉样β (Aβ) 的大脑积累与阿尔茨海默病 (AD) 病原发生有关.
负责粉样蛋白传播和神经毒性的Aβ的特定形式仍然不清楚.
在动物模型中,AD大脑的同质化加速了粉样蛋白病理,但播种物种定义不好.

研究的目的:

为了评估来自人类AD大脑的扩散性Aβ形式的播种活动.
研究可溶性Aβ在加速粉样蛋白病理和神经退行症中的作用.
为了确定来自AD大脑的扩散性Aβ是否可以诱导Aβ聚合和相关的病理.

主要方法:

从人类AD中制备可溶性"S提取物",并通过缓冲浸泡和离心,控制大脑组织.
脑内注射AD或控制大脑S提取物到App的小鼠中.
评估行为变化 (学习行为),大脑粉样蛋白沉积,神经炎症 (微结质症,星细胞症),神经元缩和突触损失.

主要成果:

在AD脑内注射AD脑S提取物显著加快了amyloid沉积,神经炎症,神经元缩和突触损失在App^NL-F/NL-F小鼠.
艾滋病大脑S提取物注射导致十个月内学会行为的显著扰乱.
控制大脑S提取物没有改变学习行为或诱导粉样蛋白病理,表明AD衍生的Aβ播种的特异性.

结论:

来自AD大脑的可溶性提取物中存在的扩散性Aβ形式是粉样蛋白聚合和相关病理的强有力的诱导剂.
这些可溶性Aβ物种可以加速神经退行和阿尔茨海默病的特征认知缺陷.
针对这些扩散性Aβ物种可能为阿尔茨海默病提供治疗策略.

关键词:

氨基胺β-蛋白质是什么认知障碍认知障碍是一种认知障碍.格里奥西斯 (gliosis) 是一种疾病.发生神经元损失.神经毒性神经毒性像子一样的传播,像子一样的传播.可溶性聚合物是一种可溶性聚合物.

更多相关视频

Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease

Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease

Published on: April 19, 2021

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections

Published on: May 19, 2022

相关概念视频

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Alzheimer Disease l: Introduction

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...

Alzheimer Disease ll: Pathophysiology

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...